Group 1 - The AI medical concept is experiencing significant activity, with companies like Dean Diagnostics and Hongbo Pharmaceutical hitting the 20% daily limit increase [1] - Meian Health has achieved a three-day consecutive increase, indicating strong market interest [1] - Other companies such as Jiahe Meikang and Chengdu Xian Dao have seen increases of over 10%, while Anbiping, Weining Health, Yaoshi Technology, and Guoxin Health are also following the upward trend [1]

证券日报网讯 1月12日，泓博医药发布公告称，公司股票交易价格于2026年1月9日、1月12日连续两个 交易日收盘价格涨幅偏离值累计超过30%，根据《深圳证券交易所交易规则》的相关规定，属于股票交 易异常波动的情形。 （文章来源：证券日报） ...

两融数据显示，该股最新(1月9日)两融余额为2.32亿元，其中，融资余额为2.32亿元，近10日增加 1861.92万元，环比增长8.74%。 证券时报·数据宝统计显示，泓博医药所属的医药生物行业，目前整体涨幅为0.12%，行业内，目前股价 上涨的有198只，涨停的有迪安诊断、美年健康等3只。股价下跌的有276只，跌幅居前的有海思科、三 生国健、益诺思等，跌幅分别为6.41%、4.22%、4.20%。 泓博医药股价创出历史新高，截至9:43，该股上涨9.48%，股价报45.15元，成交量1164.15万股，成交金 额5.20亿元，换手率9.27%，该股最新A股总市值达63.02亿元，该股A股流通市值56.72亿元。 公司发布的三季报数据显示，前三季度公司共实现营业收入5.14亿元，同比增长31.43%，实现净利润 3474.96万元，同比增长127.96%，基本每股收益为0.2489元，加权平均净资产收益率3.30%。 ...

证券代码：301230 证券简称：泓博医药 公告编号：2026-002 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、公司股票交易异常波动的具体情况 上海泓博智源医药股份有限公司 上海泓博智源医药股份有限公司（以下简称"公司"）股票交易价格于 2026 年 1 月 9 日、1 月 12 日连续两个交易日收盘价格涨幅偏离值累计超过 30%，根据《深圳证 券交易所交易规则》的相关规定，属于股票交易异常波动的情形。 二、公司关注并核实情况 针对公司股票交易异常波动，公司对有关事项进行了核查，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响 的未公开重大信息； 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、公司、控股股东和实际控制人不存在关于公司应披露而未披露的重大事项，或 处于筹划阶段的重大事项； 5、股票异常波动期间，控股股东、实际控制人未发生买卖公司股票的行为； 6、公司不存在违反公平信息披露规定的情形。 三、是否存在 ...

Company Performance - Hongbo Pharmaceutical's stock price reached a historical high, increasing by 9.48% to 45.15 yuan, with a trading volume of 11.64 million shares and a transaction value of 520 million yuan, resulting in a turnover rate of 9.27% [2] - The company's latest A-share total market capitalization is 6.302 billion yuan, and the A-share circulating market capitalization is 5.672 billion yuan [2] - For the first three quarters, the company achieved an operating income of 514 million yuan, representing a year-on-year growth of 31.43%, and a net profit of 34.7496 million yuan, with a year-on-year increase of 127.96% [2] Industry Overview - The pharmaceutical and biotechnology industry overall saw a slight increase of 0.12%, with 198 stocks rising and 3 stocks hitting the daily limit, including Di'an Diagnostics and Meian Health [2] - Conversely, 276 stocks experienced declines, with the largest drops recorded by Haishike, Sansheng Guojian, and Yinuosi, with declines of 6.41%, 4.22%, and 4.20% respectively [2] Financing Data - As of January 9, the latest margin trading balance for Hongbo Pharmaceutical was 232 million yuan, with a financing balance of 232 million yuan, reflecting an increase of 18.6192 million yuan over the past 10 days, which is a growth of 8.74% [2]

Group 1 - The core point of the news is that Hongbo Pharmaceutical's stock has risen by 7.01% on January 12, reaching a price of 44.13 yuan per share, with a total market capitalization of 6.16 billion yuan, and a cumulative increase of 29.32% over the past three days [1] - Hongbo Pharmaceutical, established on December 14, 2007, focuses on drug discovery, pharmaceutical process research and development, and the commercial production of raw material intermediates, with revenue composition of 52.67% from drug discovery, 35.00% from commercial production, 8.10% from process research and development, and 4.23% from other sources [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A Fund (200006) holds 1.601 million shares of Hongbo Pharmaceutical, representing 2.08% of the circulating shares, with a floating profit of approximately 4.6267 million yuan today and a total floating profit of 14.9687 million yuan over the past three days [2][3] - The Longcheng Consumption Value Mixed A Fund has a total scale of 516 million yuan, with a year-to-date return of 17.29%, ranking 26 out of 9012 in its category, and a one-year return of 40.7%, ranking 3084 out of 8157 [2] - The fund manager, Long Yufei, has been in position for 8 years and 89 days, with the best fund return during his tenure being 61.42% and the worst being -8.9% [2]

Group 1 - The core viewpoint of the article highlights the strong performance of AI healthcare and pharmaceutical concepts in the early trading session, with specific companies like Dean Diagnostics and Meien Health achieving consecutive gains [1] - Companies such as Ruizhi Medicine, Innotech, Hongbo Medicine, and Weining Health also experienced upward movement in their stock prices, indicating a broader trend in the sector [1]

Group 1 - The sixth Asian Beach Games will hold a press conference on January 12, 2023, to discuss the preparation status [2] - Shanghai Disneyland will implement a tiered refund policy starting January 12, 2026, allowing full refunds up to 7 days before the visit [3] - A total of 9 companies will have their restricted shares unlocked on January 12, with a total unlock volume of 742 million shares, valued at 17.761 billion [4] Group 2 - One company has disclosed its stock repurchase progress, with BOE Technology Group completing a repurchase amounting to 1.5 billion [5] - Seven A-shares will undergo equity registration on January 12, with significant dividends announced, including Hai Kan Co. distributing 5.20 yuan per 10 shares [6] - Economic data such as the Eurozone Sentix Investor Confidence Index and India's CPI for December 2025 will be released [7]

（文章来源：证券时报网） 数据宝统计，截至14:42，泓博医药成交额10.06亿元，创2025年2月18日以来新高。最新股价上涨 19.99%，换手率20.88%。上一交易日该股全天成交额为4.60亿元。（数据宝） ...

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].